433 related articles for article (PubMed ID: 24185378)
21. Design, synthesis and evaluation of novel N-hydroxybenzamides/N-hydroxypropenamides incorporating quinazolin-4(3H)-ones as histone deacetylase inhibitors and antitumor agents.
Hieu DT; Anh DT; Tuan NM; Hai PT; Huong LT; Kim J; Kang JS; Vu TK; Dung PTP; Han SB; Nam NH; Hoa ND
Bioorg Chem; 2018 Feb; 76():258-267. PubMed ID: 29223029
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
Lee S; Shinji C; Ogura K; Shimizu M; Maeda S; Sato M; Yoshida M; Hashimoto Y; Miyachi H
Bioorg Med Chem Lett; 2007 Sep; 17(17):4895-900. PubMed ID: 17588744
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group.
Chen PC; Patil V; Guerrant W; Green P; Oyelere AK
Bioorg Med Chem; 2008 May; 16(9):4839-53. PubMed ID: 18397827
[TBL] [Abstract][Full Text] [Related]
24. Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity.
Huong TT; Dung DT; Huan NV; Cuong LV; Hai PT; Huong LT; Kim J; Kim YG; Han SB; Nam NH
Bioorg Chem; 2017 Apr; 71():160-169. PubMed ID: 28196602
[TBL] [Abstract][Full Text] [Related]
25. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis and biological evaluation of novel hydroxamic acids bearing artemisinin skeleton.
Ha VT; Kien VT; Binh le H; Tien VD; My NT; Nam NH; Baltas M; Hahn H; Han BW; Thao do T; Vu TK
Bioorg Chem; 2016 Jun; 66():63-71. PubMed ID: 27018835
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
[TBL] [Abstract][Full Text] [Related]
29. A hybrid of thiazolidinone with the hydroxamate scaffold for developing novel histone deacetylase inhibitors with antitumor activities.
Yang F; Peng S; Li Y; Su L; Peng Y; Wu J; Chen H; Liu M; Yi Z; Chen Y
Org Biomol Chem; 2016 Feb; 14(5):1727-35. PubMed ID: 26732459
[TBL] [Abstract][Full Text] [Related]
30. Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
Chao SW; Chen LC; Yu CC; Liu CY; Lin TE; Guh JH; Wang CY; Chen CY; Hsu KC; Huang WJ
Eur J Med Chem; 2018 Jan; 143():792-805. PubMed ID: 29223096
[TBL] [Abstract][Full Text] [Related]
31. Structure-activity relationship studies of novel oxygen-incorporated SAHA analogues.
Kim SA; Jin YL; Kim HS
Arch Pharm Res; 2009 Jan; 32(1):15-21. PubMed ID: 19183872
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
[TBL] [Abstract][Full Text] [Related]
33. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
34. Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid.
Bieliauskas AV; Weerasinghe SV; Pflum MK
Bioorg Med Chem Lett; 2007 Apr; 17(8):2216-9. PubMed ID: 17307359
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and biological evaluation of 4-anilinothieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as novel histone deacetylase inhibitors.
Yang W; Li L; Ji X; Wu X; Su M; Sheng L; Zang Y; Li J; Liu H
Bioorg Med Chem; 2014 Nov; 22(21):6146-55. PubMed ID: 25261927
[TBL] [Abstract][Full Text] [Related]
36. Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment.
Chen L; Wilson D; Jayaram HN; Pankiewicz KW
J Med Chem; 2007 Dec; 50(26):6685-91. PubMed ID: 18038969
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors.
Zhu Y; Chen X; Wu Z; Zheng Y; Chen Y; Tang W; Lu T
Arch Pharm Res; 2012 Oct; 35(10):1723-32. PubMed ID: 23139122
[TBL] [Abstract][Full Text] [Related]
38. Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.
Yang F; Zhao N; Song J; Zhu K; Jiang CS; Shan P; Zhang H
Molecules; 2019 Jul; 24(14):. PubMed ID: 31311163
[TBL] [Abstract][Full Text] [Related]
39. Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
Bouchain G; Leit S; Frechette S; Khalil EA; Lavoie R; Moradei O; Woo SH; Fournel M; Yan PT; Kalita A; Trachy-Bourget MC; Beaulieu C; Li Z; Robert MF; MacLeod AR; Besterman JM; Delorme D
J Med Chem; 2003 Feb; 46(5):820-30. PubMed ID: 12593661
[TBL] [Abstract][Full Text] [Related]
40. Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.
Liu R; Wang J; Tang W; Fang H
Bioorg Med Chem; 2016 Apr; 24(7):1446-54. PubMed ID: 26907204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
